Compounded tirzepatide does expire, and its usable window is typically much shorter than the expiration date you would see on a manufacturer-produced vial. That window is defined by a Beyond Use Date, commonly abbreviated as BUD. Unlike an expiration date stamped by a pharmaceutical company after years of formal stability testing, a BUD reflects the timeframe within which a compounding pharmacy can reasonably assure sterility and chemical integrity. For patients relying on compounded tirzepatide, understanding what a BUD means, how it is set, and what can go wrong when it passes is surprisingly practical knowledge, especially given that a striking number of compounding pharmacies barely disclose this information at all.
What a Beyond Use Date Is and Why It Is Not the Same as an Expiration Date
An expiration date on a branded medication like Mounjaro comes from extensive stability studies that can span years. The manufacturer tests the drug under controlled conditions, measures how much active ingredient remains over time, checks for degradation products, and submits the data to the FDA. The result is a date that reflects real, tested chemical shelf life.
A Beyond Use Date works differently. It applies specifically to compounded preparations, which are mixed by a pharmacy rather than manufactured at scale. Because compounding pharmacies do not typically run the same multi-year stability programs that large drug companies do, USP Chapter 797, the standard that governs sterile compounding in the United States, sets default BUD limits based on the risk category of the preparation and the conditions under which it was compounded. Establishing an appropriate BUD requires a thorough evaluation of concentration, storage parameters, and supporting resources for the specific compounded product. The goal is to ensure each preparation remains both sterile and chemically stable for the duration a patient will use it.1PubMed Central. Guidelines for the Establishment of Appropriate Beyond Use Dating of Sterile Compounded Admixtures
The practical upshot for patients: the BUD on your compounded tirzepatide vial is not a rough guideline or a conservative estimate with a big safety margin baked in. It is the outer boundary of what the pharmacy can support, and in many cases it is already the most generous date their testing or default regulations allow.
How USP 797 Shapes the BUD on Compounded Tirzepatide
USP Chapter 797 divides sterile compounded preparations into risk categories based on how they are prepared and the conditions in the compounding area. The default BUDs for each category are quite short. If a pharmacy does not conduct its own sterility testing program, the chapter requires them to use the default short BUDs that correspond to their preparation’s risk level.2Semantic Scholar. Basics of compounding: considerations for implementing United States Pharmacopeia chapter 797 pharmaceutical compounding-sterile preparations, part 8: stability and beyond-use dating For low-risk preparations stored at controlled room temperature, that can mean a matter of days. Refrigerated storage extends it somewhat, but even then the window is far shorter than what you might expect from a commercially manufactured injectable.
A compounding pharmacy can extend its BUD beyond the USP defaults, but only by conducting or citing stability studies specific to their formulation. That means testing the exact concentration, the exact vehicle, and the exact container-closure system they use. Generic data from a different formulation or a different peptide does not count. This is where things get tricky with tirzepatide, because the compound is relatively new in the compounding space, and published stability data for specific compounded formulations remains limited.
Some pharmacies invest in third-party stability testing and can offer BUDs of weeks or even a few months under refrigeration. Others rely on the conservative USP defaults and ship product that needs to be used within a narrow window. As a patient, the BUD printed on your vial is only as reliable as the testing behind it, and that testing varies enormously from one compounder to another.
Most Compounders Do Not Even Tell You
One of the more frustrating realities of the compounded tirzepatide market is how little information many pharmacies provide about shelf life and storage. A review of compounded semaglutide and tirzepatide products found that only about 18% reported information about their Beyond Use Date and preferred storage conditions. Roughly 28% reported preferred storage conditions at all.3PubMed. Compounded Semaglutide and Tirzepatide Products Use Unique Formulations but Efficacy and Safety Largely Unknown
That means the vast majority of compounded products in this space ship to patients with minimal or no clarity about when the product should be discarded or how to store it. This is not a minor labeling oversight. Without a clearly stated BUD, you have no way to know whether the vial sitting in your refrigerator is still safe and effective. You are essentially trusting that the pharmacy handled everything correctly and that the product will hold up, with no verifiable timeline to guide you.
If your compounded tirzepatide arrives without a BUD printed on the vial or included in the packaging, that itself is a red flag. A reputable compounder will label every vial with its Beyond Use Date and provide storage instructions. If you have to ask for this information, ask before you order.
What Actually Happens to a Peptide as It Degrades
Tirzepatide is a synthetic peptide, a chain of amino acids designed to mimic specific hormones. Peptides are inherently less stable than small-molecule drugs like ibuprofen or metformin. Over time, and faster when stored improperly, several things can go wrong with a compounded peptide formulation.
The most common degradation pathway is chemical breakdown. Amino acids in the peptide chain can undergo oxidation, deamidation, or hydrolysis, processes where bonds break or chemical groups change. The result is a molecule that no longer has the same shape or activity as the original drug. Stability-indicating assays used in pharmaceutical testing are designed to measure exactly this: how the concentration of the intact active ingredient changes over time and how much degradation product accumulates.4PubMed Central. Choices of chromatographic methods as stability indicating assays for pharmaceutical products: A review But unless a compounder actually runs these tests on their specific formulation, no one knows at what rate the tirzepatide in your vial is breaking down.
Aggregation is the other major concern. Peptides in solution can stick together and form clumps, especially when exposed to heat, agitation, or repeated temperature changes. These aggregates may not be visible to the naked eye, but they change how the drug behaves in your body. A solution that looks clear can still contain problematic levels of aggregated peptide.
Why Light Exposure Matters More Than You Might Think
Peptide and protein formulations are sensitive to light in ways that many patients do not expect. Ultraviolet light is the obvious culprit, but even ordinary visible light in the 400 to 800 nanometer range can cause photooxidation of proteins, potentially impairing their integrity.5PubMed Central. Protein photodegradation in the visible range? Insights into protein photooxidation with respect to protein concentration Therapeutic protein and peptide formulations are particularly vulnerable to photo-degradation from near-UV and visible light exposure.6PubMed Central. Advanced Oxidation Processes in Pharmaceutical Formulations: Photo-Fenton Degradation of Peptides and Proteins
This is why compounded tirzepatide should be stored in its original packaging, away from windows, countertops with overhead lighting, and certainly not left sitting out during the day. A vial that sits on a bathroom shelf under fluorescent light for weeks is not in the same condition as one stored in a dark refrigerator. The degradation from light exposure is cumulative and invisible. The solution will not change color or smell different. The peptide just quietly loses activity, and the breakdown products accumulate.
If your compounded tirzepatide comes in a clear vial without any secondary packaging to block light, store it inside an opaque bag or a closed box in the refrigerator. This is a small step that makes a real difference over the life of the product.
Microbial Risks After the BUD
Chemical degradation is one concern. Microbial contamination is another, and it carries more immediate health risks. Compounded sterile preparations are made in controlled environments, but the moment you puncture a vial with a needle at home, you introduce potential contaminants. Multi-dose vials, which are common in compounded tirzepatide, get punctured repeatedly over their use period, creating multiple opportunities for bacteria to enter.
Preservatives in the formulation provide some defense. Research on GLP-1 receptor agonist self-injectors, which share a similar use pattern, found that common preservatives in these formulations killed E. coli within 60 to 90 minutes of contamination at room temperature.7Scholars Academic Journal of Pharmacy. Verifying the Safety of Microbial Contamination in Self-Injectors of Glucagon-like peptide-1 Receptor Agonists That is reassuring, but it depends on the preservative system being intact and at an effective concentration. Over time, preservatives themselves can degrade, particularly if the product has been exposed to heat or light. Once the preservative system weakens, a multi-dose vial becomes a more hospitable environment for microbial growth.
The BUD accounts for this. It is set assuming that the preservative system will remain effective and that the product will be stored properly throughout its assigned shelf life. Using a vial past its BUD means you are outside the window where anyone has verified that the preservative is still doing its job. For a product you inject subcutaneously, that is not a gamble worth taking.
Immune Reactions from Degraded Peptides
Beyond reduced effectiveness, there is a less obvious risk to using compounded tirzepatide past its BUD: your immune system might react to the degradation products. Immunogenicity, the tendency of a therapeutic peptide to trigger an unwanted immune response, is a recognized concern with peptide-based drugs. This response can be triggered not just by the peptide itself but also by impurities that accumulate during production, storage, or degradation, leading to the development of antidrug antibodies.8PubMed Central. Beyond Efficacy: Ensuring Safety in Peptide Therapeutics through Immunogenicity Assessment
When tirzepatide degrades, the fragments and altered molecules that form are not just inactive junk. They can look foreign to your immune system in ways the intact peptide does not. Aggregated peptides are particularly immunogenic because clumps of misfolded protein can activate immune pathways more readily than individual molecules. If your body develops antibodies against tirzepatide or its breakdown products, those antibodies can neutralize future doses, reducing or eliminating the drug’s effectiveness even when you switch to a fresh, properly stored vial.
This is not a theoretical risk. Immunogenicity is monitored in clinical trials of all peptide therapeutics precisely because it happens often enough to matter. Injecting a degraded product raises the odds. The fewer degradation products in each dose, the lower the immunogenic risk, which is one more reason the BUD exists.
Refrigeration, Freezing, and the Temperature Question
Most compounded tirzepatide should be refrigerated at roughly 36 to 46°F (2 to 8°C). This slows both chemical degradation and microbial growth. Some pharmacies allow brief periods at room temperature for patient convenience, similar to the guidance for branded GLP-1 medications, but the total time outside the refrigerator chips away at the remaining shelf life.
Freezing is generally not recommended for compounded peptide solutions unless the pharmacy specifically states otherwise. Freezing and thawing can cause physical stress on the peptide molecules, promoting aggregation and potentially disrupting the preservative system. Even if the solution looks normal after thawing, the damage may be invisible. Some patients store vials in the freezer hoping to extend the BUD; this is counterproductive unless the formulation was specifically tested for freeze-thaw stability.
Temperature excursions during shipping are another underappreciated issue. If your compounded tirzepatide arrives warm, the insulated packaging was inadequate, or it sat on a hot porch for hours, the clock on degradation has been running faster than intended. A product that was compounded with a 60-day refrigerated BUD does not actually have 60 days left if it spent 18 hours at 90°F during transit. Reputable compounders ship with cold packs and insulated containers, but you should check the temperature of the package when it arrives. If the cold packs are fully melted and the vials are warm to the touch, contact the pharmacy before using the product.
How to Read and Use the BUD on Your Vial
The BUD should be printed directly on the vial label, usually formatted as a calendar date. Some pharmacies also include the date of compounding, which lets you calculate the total assigned shelf life. A few things to keep in mind when working with this information:
- The BUD assumes proper storage: The date is only valid if you have kept the product refrigerated (or at whatever temperature the pharmacy specifies) since you received it. Time spent at room temperature or exposed to light shortens the effective shelf life even if the printed date has not passed.
- Multi-dose vials have a use-period limit: Even within the BUD, many compounders specify a maximum number of days after first puncture. Once you draw the first dose, a separate clock starts. This is typically 28 days for preserved multi-dose injectables, though it can vary by formulation.
- Visual inspection is necessary but not sufficient: Before each injection, check the solution for particles, cloudiness, or discoloration. If anything looks off, discard the vial. But a clear solution does not guarantee the product is still good. Chemical degradation and early-stage aggregation are invisible.
- Do not pool leftover product: If you have small amounts left in multiple vials near their BUD, do not combine them into one vial. This introduces contamination risk and mixes product of different ages.
Discarding product that still has liquid in it feels wasteful, especially given the cost of compounded tirzepatide. But the BUD exists because the chemistry of the product changes in ways you cannot see, smell, or feel. A dose that has lost 20% of its potency will not hurt in the same way a contaminated dose might, but it will underperform, and inconsistent dosing undermines the whole reason you are taking the medication.
Compounded Versus Manufactured Tirzepatide Shelf Life
Branded Mounjaro, the commercially manufactured form of tirzepatide, carries a shelf life measured in years when stored properly before first use. Eli Lilly conducted extensive real-time and accelerated stability studies to earn that dating. The autoinjector pens are also designed with container-closure systems specifically engineered to protect the peptide from light, oxygen, and contamination.
Compounded tirzepatide, by contrast, typically uses standard pharmaceutical vials and rubber stoppers, which are adequate but not purpose-built for this particular molecule. The formulation itself often differs from the branded version: different buffers, different preservatives, different concentrations. Each of these variables affects stability independently. The review finding that only about 18% of compounded products reported BUD information suggests that many compounders may not even have rigorous stability data for their own formulations.3PubMed. Compounded Semaglutide and Tirzepatide Products Use Unique Formulations but Efficacy and Safety Largely Unknown
This gap is not an argument against compounded tirzepatide per se. It is an argument for choosing a compounder that provides a clearly labeled BUD, can explain the testing behind it, and gives you specific storage instructions. Pharmacies that are transparent about their stability data are pharmacies that have stability data. The ones that are vague about it may not.
When You Suspect Your Product Has Gone Bad
Sometimes the signs are obvious: visible particles floating in the solution, a cloudy or hazy appearance, or a change in color. Any of these mean the vial should be discarded immediately, regardless of the BUD. But the trickier scenario is when the product looks perfectly fine and you suspect it has lost potency based on your response to it.
If you have been on a stable dose of compounded tirzepatide and suddenly notice that your appetite suppression has weakened, your blood sugar is creeping up, or your weight loss has stalled, the product itself could be the issue. This is not always the case since bodies adapt and plateaus happen for other reasons, but it is worth considering, especially if the change coincides with a new shipment or a vial that is approaching its BUD. Contact your prescriber and your compounding pharmacy. A good pharmacy will take the concern seriously and may ask you to return the vial for testing.
Keeping a log of when you receive each shipment, the BUD on each vial, and when you start and finish each vial can help you spot patterns. If efficacy issues consistently track with vials from a particular batch or vials used near the end of their BUD, that is useful information for both you and your provider.